首页> 外文期刊>Advances in Breast Cancer Research >Up to Date Management of DCIS and Future Directions
【24h】

Up to Date Management of DCIS and Future Directions

机译:最新的DCIS和未来方向管理

获取原文
       

摘要

Ductal carcinoma in situ (DCIS) is a non-invasive malignancy confined within the basement membrane of the breast ductal system. There is a lot of disparity in the natural history of DCIS with an estimated incidence of progression to invasive ductal carcinoma between 20% to 53% over ten or more years afte r initial diagnosis. The surgical and adjuvant management of DCIS has advanced significantly in the last couple of decades. Nonetheless, surgeons, medical oncologist s , and radiation oncologists, along with their patients, still depend on conve ntional clinical and pathologic risk factors to make management decisions. Irrespective of the management strategy, long-term survival is excel lent. The debate around DCIS relates to preventing either under-treatment or over-treatment. In this paper, we will review the incidence and management options of DCIS. Additionally, we will focus on several current disputes related to the management of DCIS, including breast conserving surgery, the role of radiation in breast conservation surgery, sentinel node biopsy in DCIS, hormonal therapy, various risk stratification schemes, and the option of active surveillance for low-risk DCIS.
机译:导管癌原位(DCIS)是一种非侵入性恶性肿瘤,局限于乳房导管系统的基底膜内。 DCIS的自然病史存在很多差异,估计进展的发生率为侵入性导管癌的发生率为20%至53%以上的初步诊断。在过去的几十年中,DCIS的外科和佐剂管理显着提出。尽管如此,外科医生,医学肿瘤科和辐射肿瘤学家以及患者仍然依赖于诊断临床和病理风险因素来制定管理决策。无论管理策略如何,长期生存都是Excel Lent。 DCIS周围的辩论涉及防止治疗后或过度治疗。在本文中,我们将审查DCIS的发病率和管理方案。此外,我们将重点关注与DCI的管理有关的几项相关争议,包括乳房保守手术,辐射在乳房保护手术中的作用,DCIS中的Sentinel节点活组织检查,荷尔蒙治疗,各种风险分层方案以及主动监测的选择对于低风险的DCIS。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号